mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Company profile
Ticker
MIRM
Exchange
Website
CEO
Christopher Peetz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Mirum Pharmaceuticals AG, a company • Mirum Pharmaceuticals International B.V., a company ...
IRS number
831281555
MIRM stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
NT 10-K
Notice of late annual filing
28 Feb 24
8-K
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8 Jan 24
8-K
Other Events
18 Dec 23
S-8
Registration of securities for employees
2 Nov 23
424B5
Prospectus supplement for primary offering
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Transcripts
MIRM
Earnings call transcript
2023 Q4
28 Feb 24
MIRM
Earnings call transcript
2023 Q3
2 Nov 23
MIRM
Earnings call transcript
2023 Q2
3 Aug 23
MIRM
Earnings call transcript
2023 Q1
6 May 23
MIRM
Earnings call transcript
2023 Q1
4 May 23
MIRM
Earnings call transcript
2022 Q4
8 Mar 23
MIRM
Earnings call transcript
2022 Q3
9 Nov 22
MIRM
Earnings call transcript
2022 Q2
7 Aug 22
MIRM
Earnings call transcript
2022 Q1
7 May 22
MIRM
Earnings call transcript
2021 Q4
10 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 163 |
Opened positions | 33 |
Closed positions | 20 |
Increased positions | 68 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 1.52 tn |
Total shares | 60.98 mm |
Total puts | 43.70 k |
Total calls | 43.20 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Frazier Life Sciences Management | 6.47 mm | $204.46 bn |
Biotechnology Value Fund L P | 4.37 mm | $125.94 mm |
BVF | 4.37 mm | $138.09 bn |
Eventide Asset Managment | 3.96 mm | $125.09 bn |
Frazier Life Sciences IX | 3.57 mm | $94.27 mm |
NEA Management | 2.19 mm | $69.09 bn |
New Enterprise Associates 16 | 2.19 mm | $65.78 mm |
BLK Blackrock | 2.11 mm | $66.78 bn |
JHG Janus Henderson | 1.92 mm | $60.78 bn |
Rock Springs Capital Management | 1.82 mm | $57.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Eric Bjerkholt | Common Stock | Buy | Acquire P | No | No | 24.8 | 2,000 | 49.60 k | 14,000 |
25 Mar 24 | Radovich Peter | Common Stock | Sell | Dispose S | No | No | 25.8 | 4,303 | 111.02 k | 29,013 |
18 Mar 24 | Eric Bjerkholt | Common Stock | Buy | Acquire P | No | No | 25.8 | 2,000 | 51.60 k | 12,000 |
2 Feb 24 | Radovich Peter | Common Stock | Sell | Dispose S | No | No | 26.1917 | 1,790 | 46.88 k | 34,695 |
2 Feb 24 | Christopher Peetz | Common Stock | Sell | Dispose S | No | No | 26.1918 | 6,013 | 157.49 k | 104,112 |
News
Analyst Ratings For Mirum Pharmaceuticals
17 Apr 24
Stifel Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $48
17 Apr 24
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
2 Apr 24
Mirum Pharmaceuticals' LIVMARLI Receives Reimbursement Recommendation By Canada's CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome
2 Apr 24
$5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying
28 Mar 24
Press releases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Apr 24
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
2 Apr 24
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
13 Mar 24
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Mar 24